Sienna Test Kits




Connecting World Merchandise, LLC is Proud to Announce:

We have Developed and launched one of the world’s first rapid point-of-care lateral flow immunoassays to aid in the diagnosis of coronavirus infection.

The test detects both early marker and late marker, IgM/IgG antibodies in human finger-prick (capillary) or venous whole blood, serum, and plasma samples.

There is a critical, global need for serology assays that can complement nucleic acid (PCR) tests for diagnosing COVID-19 infection.

Knowledge of prior infection is epidemiologically important and represents a significant unmet need in the management of the COVID-19 pandemic.

Features & Benefits
Rapid IgM-IgG Combined Antibody Test for COVID-19 is used to qualitatively detect IgG and IgM antibodies of the novel corona virus in human serum, plasma or whole blood in vitro.

Works with whole blood, serum, & plasma
Tests for both IgM and IgG antibodies
Validated using PCR

10-15 minutes per test
Intuitive visual interpretation
No special equipment needed

WE CAN Change Everything

This is a point-of-care lateral flow immunoassay (LFIA) test product, which can detect IgM and IgG simultaneously in human blood within 15 minutes.

The results demonstrated this rapid antibody test has high sensitivity and specificity.

It can be used in hospitals, clinics, and testing laboratories.

Our test can also be effectively deployed in businesses, schools, airports, seaports and train stations, etc... giving it the potential to become a compelling force in the fight against this global threat.

Global interventions include delaying resumption of workplaces, and encouraging citizens to stay and work from home, and so on.

Most test kits suffer from many limitations:

1) These tests have long turnaround times and are complicated in operation; they generally take on average over 2 to 3 hours to generate results.

2) The PCR tests require certified laboratories, expensive equipment and trained technicians to operate.

3) There are some numbers of false negatives for RT-PCR of COVID-19. These limitations make RT-PCR unsuitable for use in the field for rapid and simple diagnosis and screening of patients.

It limits the outbreak containment effort.

Therefore, there is an urgent need for a rapid, simple to use, sensitive, and accurate test to quickly identify infected patients of SARS-CoV-2 to prevent virus transmission and to assure timely treatment of patients.